Want to see ARTV full AI Analyst Report?
ARTV Stock Chart & Stats
$11.77
$0.57(5.68%)
At close: 4:00 PM EDT
$11.77
$0.57(5.68%)
Day’s Range― - ―
52-Week Range$2.71 - $14.53
Previous CloseN/A
Volume33.82K
Average Volume (3M)448.70K
Market Cap
$330.99M
Enterprise Value$42.76M
Total Cash (Recent Filing)$349.39M
Total Debt (Recent Filing)$9.85M
Price to Earnings (P/E)―
Beta2.69
Next Earnings
Nov 18, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding48,890,120
10 Day Avg. Volume438,218
30 Day Avg. Volume448,696
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-64.21
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$38.00Price Target Upside222.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage reduces refinancing pressure and preserves financial flexibility relative to a more heavily indebted development-stage biotech. The modest debt burden may leave management greater room to direct capital toward research and operations, although it does not offset the company’s losses.
Stronger CapitalizationThe substantial increase in reported equity indicates a stronger capitalization base than in the prior period. That can provide a broader funding platform for ongoing development activities and reduce balance-sheet strain, even though the company remains dependent on financing while returns are deeply negative.
Governance ContinuityThe completed director elections provide multi-year board continuity, while auditor ratification supports the existing financial-reporting oversight framework. Stable governance can help maintain strategic focus and execution discipline as Artiva manages development activities and its need for external capital.
Bears Say
No Current Revenue BaseZero reported revenue alongside a large ongoing net loss shows that Artiva has not yet established commercial scale in the latest periods. Without an operating revenue base, the company has limited internal funding capacity and remains exposed to prolonged development timelines and execution requirements.
Heavy Cash BurnPersistent operating and free-cash-flow deficits convert the company’s losses into substantial cash consumption rather than primarily non-cash charges. Continued burn increases dependence on future financing and can constrain investment flexibility, particularly if development spending remains elevated over the next several quarters.
Equity Dilution RiskExpanding the equity incentive plan increases the pool of shares that may be issued for employee and executive compensation. While this can support talent retention, additional share capacity creates a durable dilution risk for existing holders and may compound the effects of future financing dependence.
Artiva Biotherapeutics, Inc. News
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $2.71 and its highest was $14.53 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $330.99M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 35 days.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.625 by -$0.005.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 48,890,120 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.625. Following the earnings report the stock price went down -2.677%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artiva Biotherapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (222.85% Upside)
$38.00 (222.85% Upside)
Blogger Sentiment
Bullish
ARTV Sentiment 75%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 13.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
140.92%
12-Months-Change
Fundamentals
Return on Equity
-53.86%
Trailing 12-Months
Asset Growth
117.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
ARTV Stock 12 Month Forecast
Average Price Target
$38.00
▲(222.85% Upside)
Technical Analysis
Ownership Overview
55.93% Insiders
1.16% Mutual Funds
4.98% Other Institutional Investors
34.95% Public Companies and
Individual Investors